NASDAQ$ACRS
Aclaris Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Aclaris Therapeutics' Q4 2024 financial results were reported, marked by a decrease in revenue primarily due to the absence of a one-time upfront payment received in the prior year, alongside a net loss impacted by in-process research and development expenses.
Aclaris Therapeutics reported Q4 2024 financial results, featuring a revenue of $9.2 million and a net loss of $96.6 million. The company highlighted its cash runway extending into 2028 and progress in its clinical development programs.
- Aclaris reported Q4 2024 revenue of $9.2 million, compared to $17.6 million in Q4 2023.
- The company experienced a net loss of $96.6 million for Q4 2024, compared to a net loss of $1.5 million for Q4 2023.
- Aclaris ended the year with $203.9 million in cash, cash equivalents, and marketable securities.
- The company's cash runway is expected to extend into 2028.
Headline financials
Revenue & EPS history
Aclaris Therapeutics · Revenue · Quarterly
$9.21M
Revenue by segment
Aclaris Therapeutics · $9.28M total across 2 segments · Q3 2023
- Licensing$8.58M-52.1%92.4%
- Contract research$705K-35.3%7.6%
Forward guidance
Aclaris Therapeutics anticipates a rich catalyst calendar in 2025, including Phase 2 data in multiple immuno-inflammatory disease indications. Data from CTTQ’s Phase 2 studies of Bosakitug (ATI-045) in Chinese patients with severe asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is expected in the first half of 2025 to inform internal development programs. The initiation of enrollment in the Phase 2b trial for Bosakitug in Atopic Dermatitis (AD) is on track for the first half of 2025, and the company's cash runway is expected into 2028.
Tailwinds
- Phase 2 data is expected in multiple immuno-inflammatory disease indications in 2025.
- Data from CTTQ’s Phase 2 studies of Bosakitug in Chinese patients with severe asthma and CRSwNP are expected in the first half of 2025.
- Enrollment in the Phase 2b trial for Bosakitug in Atopic Dermatitis (AD) is on track for the first half of 2025.
- The company's cash runway is expected into 2028.
- Top line results expected in the first half of 2025 for Phase 2a Trial in AD of ATI-2138.
Headwinds
- Uncertainties inherent in the conduct of clinical trials.
- Reliance on third parties over which the company may not always have full control.
- Ability to enter into strategic partnerships on commercially reasonable terms.
- Uncertainty regarding the macroeconomic environment.
- Risks and uncertainties described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-0.7%
Avg return
30 days after
38%
16 / 42 earnings
Positive
+22.7%
Q4 2018
Best reaction
-15.3%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | +1.9% | -8.8% | |
| Q4 2025 | -5.2% | -8.2% | +6.3% | |
| Q3 2025 | -4.7% | -9.7% | +23.7% | |
| Q1 2025 | -0.8% | -3.8% | +9.9% | |
| Q4 2024 | -7.1% | -8.1% | -24.3% | |
| Q3 2024 | +10.4% | +18.5% | +77.5% | |
| Q2 2024 | -4.1% | -6.6% | -4.1% | |
| Q1 2024 | -6.9% | -10.7% | -21.4% | |
| Q4 2023 | -1.7% | +2.5% | +2.5% | |
| Q3 2023 | +0.9% | -11.5% | -81.0% | |
| Q2 2023 | -12.1% | -16.5% | -23.4% | |
| Q1 2023 | -7.8% | -12.1% | +4.5% | |
| Q4 2022 | -4.9% | -1.8% | -36.9% | |
| Q3 2022 | +4.3% | +9.3% | -0.2% | |
| Q2 2022 | +18.1% | +26.8% | +20.6% | |
| Q1 2022 | -8.9% | -4.5% | +35.3% | |
| Q4 2021 | +14.3% | +11.3% | +33.5% | |
| Q3 2021 | -12.4% | -11.0% | -31.4% | |
| Q2 2021 | +4.1% | +1.4% | +21.2% | |
| Q1 2021 | -2.2% | -8.6% | -8.8% | |
| Q4 2020 | +7.8% | +12.5% | +11.4% | |
| Q3 2020 | +7.0% | +7.5% | +0.8% | |
| Q2 2020 | +11.3% | +12.8% | +9.7% | |
| Q1 2020 | +12.7% | +10.3% | +13.5% | |
| Q4 2019 | -14.0% | -20.3% | -18.2% | |
| Q3 2019 | +20.4% | +11.7% | +2.5% | |
| Q2 2019 | -11.8% | -18.8% | -1.0% | |
| Q1 2019 | -11.2% | -14.7% | -29.0% | |
| Q4 2018 | +22.7% | +8.7% | -7.8% | |
| Q3 2018 | -1.8% | -13.2% | -29.8% | |
| Q2 2018 | -4.6% | -3.9% | -11.9% | |
| Q1 2018 | -0.5% | +4.2% | +1.4% | |
| Q4 2017 | -6.7% | -12.5% | -18.4% | |
| Q3 2017 | -5.7% | -3.2% | -7.9% | |
| Q2 2017 | -0.1% | -7.1% | +1.4% | |
| Q1 2017 | +6.3% | +5.8% | +0.6% | |
| Q4 2016 | -4.9% | -5.2% | +5.8% | |
| Q3 2016 | -1.0% | -2.7% | +39.7% | |
| Q2 2016 | +3.1% | +7.0% | +15.0% | |
| Q1 2016 | -15.3% | — | — | |
| Q4 2015 | -3.9% | — | — | |
| Q3 2015 | +5.8% | — | — | |
| Q2 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro